DEA to Reclassify Marijuana in Historic US Policy Shift, Sources Say

In a significant shift from longstanding American drug policy, the U.S. Drug Enforcement Administration (DEA) is set to reclassify marijuana as a less dangerous drug, sources confirmed to The Associated Press. This move, still pending review by the White House Office of Management and Budget (OMB), marks a historic moment acknowledging the medical benefits of cannabis and its lower potential for abuse compared to some of the nation's most hazardous drugs. However, it stops short of legalizing recreational marijuana use.

The DEA's proposal follows President Joe Biden's call for a reassessment of federal marijuana laws in October 2022 and his initiative to pardon Americans convicted federally of simple possession. "Criminal records for marijuana use and possession have imposed needless barriers to employment, housing, and educational opportunities," Biden stated, emphasizing the need to amend these injustices.

Upon approval from OMB, the DEA plans to initiate a public comment period on reclassifying marijuana from Schedule I—a category that includes heroin and LSD—to Schedule III, which comprises substances like ketamine and some anabolic steroids. This reclassification is based on a recommendation from the federal Health and Human Services Department and could significantly impact various sectors across the country.

The potential reclassification has sparked a debate among experts and officials. While some view it as a positive step towards focusing resources on combating more dangerous drugs like fentanyl, others express concerns about marijuana being a "gateway drug." Meanwhile, a group of 21 Democrats led by Senate Majority Leader Sen. Chuck Schumer has advocated for removing marijuana from the controlled substances list entirely, treating it similarly to alcohol.

This policy change comes at a time when public support for marijuana legalization has reached an all-time high, with a Gallup poll last fall showing 70% of adults in favor. The move could also alleviate the heavy tax burdens faced by businesses in the rapidly growing marijuana industry, currently valued at nearly $30 billion.

Despite these potential benefits, critics warn of unintended consequences, such as the regulatory challenges faced by the approximately 15,000 cannabis dispensaries in the U.S., which would need to register with the DEA like regular pharmacies. Additionally, there are concerns about how this reclassification aligns with international treaty obligations.

The DEA's decision represents a significant policy shift that could influence various aspects of American society, from criminal justice to healthcare and business. As this proposal moves forward, it will undoubtedly continue to generate discussion on the future of marijuana regulation in the United States.